Pharmaceutical application of traditional Chinese medicine composition

Abstract

The invention discloses application of a traditional Chinese medicine composition in preparation of drugs and / or health care products for treating and / or preventing obesity, the traditional Chinese medicine composition is prepared from honeysuckle, lonicerae flos, radix achyranthis bidentatae, radix scrophulariae and dendrobe as raw materials, the ratio of the total amount of the honeysuckle and the lonicerae flos to the mass of the radix achyranthis bidentatae to the mass of the radix scrophulariae to the mass of the dendrobe is (1-200): (1-200): (1-200): (1-200), and the mass ratio of the honeysuckle to the lonicerae flos is 16: 9; or honeysuckle, radix achyranthis bidentatae, radix scrophulariae and dendrobe are used as raw materials, and the mass ratio of honeysuckle to radix achyranthis bidentatae to radix scrophulariae to dendrobe is (1-200): (1-200): (1-200): The traditional Chinese medicine composition disclosed by the invention has a relatively good effect of treating or preventing obesity, and can be used for remarkably reducing the body weight and the relative weight of peripheral adipose tissues of obese mice induced by high-fat diet, improving glucose metabolism disorder, reducing the increased TC content in serum, improving the energy metabolism level of the mice and promoting the expression of lipolysis and white fat browning related genes.

Description

Technical Field

[0001] The present invention belongs to the field of medicine and relates to pharmaceutical use of a traditional Chinese medicine composition, specifically to pharmaceutical use of a dendrobium preparation, and especially to use of a composition of honeysuckle, honeysuckle, Achyranthes bidentata, Scrophularia ningpoensis and dendrobium or a composition of honeysuckle, Achyranthes bidentata, Scrophularia ningpoensis and dendrobium in preparing medicines and / or health products for treating and / or preventing obesity. Background Art

[0002] Obesity is a chronic metabolic disease caused by the combined effects of multiple factors such as genetics and the environment, which causes an increase in the total amount of body fat or a local increase. A large amount of data research shows that obesity increases the probability of suffering from a variety of diseases such as diabetes, heart disease, hypertension, coronary atherosclerosis, and obesity. Obesity is often diagnosed clinically based on information such as the patient's body mass index, waist circumference, and body fat percentage. At present, the drugs approved by the US FDA for the treatment of obesity mainly include naltrexone / bupropion, phentermine / topiramate, orlistat, and liraglutide. The only drug approved by my country's Food and Drug Administration for the treatment of obesity is orlistat. Orlistat is an inhibitor of gastric and intestinal lipase. It improves obesity by inhibiting the decomposition and absorption of fat in food, which often causes adverse reactions such as increased gastrointestinal gas, urgency to defecate, and fatty stools. Therefore, further research and development of safe and effective drugs is of great significance for the treatment of obesity. Summary of the invention

[0003] The purpose of the present invention is to provide a use of a Chinese medicine composition in preparing medicines and / or health products for treating and / or preventing obesity in view of the current lack of safe and effective drugs for treating obesity.

[0004] The objective of the present invention is achieved through the following technical solutions:

[0005] A use of a traditional Chinese medicine composition in preparing medicines and / or health products for treating and / or preventing obesity. The traditional Chinese medicine composition is prepared from honeysuckle, Chinese honeysuckle, Achyranthes bidentata, Scrophularia ningpoensis and Dendrobium officinale as raw materials, the mass ratio of the total amount of honeysuckle and Chinese honeysuckle to Achyranthes bidentata, Scrophularia ningpoensis and Dendrobium officinale is (1-200):(1-200):(1-200):(1-200), and the mass ratio of honeysuckle to Chinese honeysuckle is 16:9; or the traditional Chinese medicine composition is prepared from honeysuckle, Achyranthes bidentata, Scrophularia ningpoensis and Dendrobium officinale as raw materials, the mass ratio of honeysuckle to Achyranthes bidentata, Scrophularia ningpoensis and Dendrobium officinale is (1-200):(1-200):(1-200):(1-200).

[0006] In the traditional Chinese medicine composition of the present invention, the combination of honeysuckle and Chinese honeysuckle in a mass ratio of 16:9 can be replaced by an equal amount of honeysuckle.

[0007] Furthermore, the total amount of honeysuckle and Chinese honeysuckle or the mass ratio of honeysuckle to Achyranthes bidentata, Scrophularia ningpoensis and Dendrobium officinale is (1-150):(1-150):(1-150):(1-150).

[0008] Furthermore, the total amount of honeysuckle and Chinese honeysuckle or the mass ratio of honeysuckle to Achyranthes bidentata, Scrophularia ningpoensis and Dendrobium officinale is (1-100):(1-100):(1-100):(1-100).

[0009] Furthermore, the total amount of honeysuckle and Chinese honeysuckle or the mass ratio of honeysuckle to Achyranthes bidentata, Scrophularia ningpoensis and Dendrobium officinale is (1-50):(1-50):(1-50):(1-50).

[0010] Furthermore, the total amount of honeysuckle and Chinese honeysuckle or the mass ratio of honeysuckle to Achyranthes bidentata, Scrophularia ningpoensis and Dendrobium officinale is (1-20):(1-20):(1-20):(1-20).

[0011] Furthermore, the total amount of honeysuckle and Chinese honeysuckle or the mass ratio of honeysuckle to Achyranthes bidentata, Scrophularia ningpoensis and Dendrobium officinale is (1-15):(1-15):(1-15):(1-15).

[0012] Furthermore, the total amount of honeysuckle and Chinese honeysuckle or the mass ratio of honeysuckle to Achyranthes bidentata, Scrophularia ningpoensis and Dendrobium officinale is (1-10):(1-10):(1-10):(1-10).

[0013] Furthermore, the total amount of honeysuckle and Chinese honeysuckle or the mass ratio of honeysuckle to Achyranthes bidentata, Scrophularia ningpoensis and Dendrobium officinale is (1-5):(1-5):(1-5):(1-5).

[0014] Furthermore, in order to have a better therapeutic effect in preventing and / or treating obesity, in a preferred embodiment, the total amount of honeysuckle and Chinese honeysuckle or the mass ratio of honeysuckle to Achyranthes bidentata, Scrophularia ningpoensis and Dendrobium officinale is (1-3):(1-3):(1-3):(1-3).

[0015] Furthermore, the total amount of honeysuckle and Chinese honeysuckle or the mass ratio of honeysuckle to Achyranthes bidentata, Scrophularia ningpoensis and Dendrobium officinale is (1-3):(1-3):1:1.

[0016] Specifically, the total amount of honeysuckle and Chinese honeysuckle or the mass ratio of honeysuckle to Achyranthes bidentata, Scrophularia ningpoensis, and Dendrobium can be 3:1:1:1, 2:1:1:1, 3:2:1:1, 3:3:1:1, 3:3:2:1, 3:3:3:1, 3:3:3:2, 1:2:1:1, 1:3:1:1, 2:3:1:1, 2:2:1:1, 1:1:1:1, etc.

[0017] Furthermore, the Chinese medicine composition is made of honeysuckle, Chinese honeysuckle, Achyranthes bidentata, Scrophularia ningpoensis and Dendrobium candidum in a mass ratio of 16:9:25:25:25.

[0018] In a preferred embodiment, the Chinese medicine composition is made of 272g of honeysuckle, 153g of honeysuckle, 425g of Achyranthes bidentata, 425g of Scrophularia ningpoensis and 425g of Dendrobium officinale.

[0019] In a preferred embodiment, the Chinese medicine composition is made of about 425 g of honeysuckle, about 425 g of Achyranthes bidentata, about 425 g of Scrophularia ningpoensis and about 425 g of Dendrobium candidum.

[0020] In a preferred embodiment, the Chinese medicine composition is made of about 1275 g of honeysuckle, about 1275 g of Achyranthes bidentata, about 425 g of Scrophularia ningpoensis and about 425 g of Dendrobium candidum.

[0021] The traditional Chinese medicine composition comprises neochlorogenic acid, chlorogenic acid, cryptochlorogenic acid, β-ecdysterone, luteolin, isochlorogenic acid B, isochlorogenic acid A, cinnamic acid and harpagoside.

[0022] As a preferred technical solution of the present invention, the Chinese medicine composition comprises one or more drugs for treating obesity.

[0023] The drug for treating obesity is selected from one or more of a liver-protecting drug, an insulin sensitizer, an antioxidant and a lipid-lowering drug.

[0024] Specifically, the drug for treating obesity is luteolin.

[0025] The Chinese medicine composition and pharmaceutical excipients are prepared into a preparation that can be administered through the intestine, non-intestinal or local route. The preparation is a solid preparation, an oral liquid preparation or an injectable liquid preparation.

[0026] The solid preparations are tablets, sustained-release tablets, dispersible tablets, buccal tablets, capsules, soft capsules, sustained-release capsules, pills, and granules; the oral liquid preparations are mixtures, emulsions, suspensions, drops or syrups, teas, juices, and beverages.

[0027] Preparations for intestinal administration include tablets, capsules, oral liquids, granules, pills, powders, pills, pastes, etc.; preparations for non-intestinal administration include injections, etc.; preparations for local administration include creams, patches, ointments, sprays, etc.

[0028] The administration route of the preparation of the present invention can be oral, sublingual, transdermal, intramuscular or subcutaneous, skin mucosa, vein, urethra, vaginal and the like.

[0029] The pharmaceutical excipients are selected from one or more of flavor correctives, clarifiers and preservatives.

[0030] The flavor corrector is selected from one or more of sucrose, lactose, other sugars, polyols (such as sorbitol, glycerol, etc.), citric acid, saccharin sodium, aspartame, sodium cyclamate and stevioside.

[0031] The clarifier is selected from one or more of sugar, sucrose, sorbitol, sucralose, saccharin sodium, sodium cyclamate, aspartame, neotame, acesulfame potassium and steviol glycosides.

[0032] The preservative is selected from one or more of benzoic acid, sorbic acid, formic acid, propionic acid or their salts (such as sodium benzoate, potassium sorbate, etc.), parabens such as methyl parahydroxybenzoate, ethyl parahydroxybenzoate, propyl parahydroxybenzoate and butyl parahydroxybenzoate.

[0033] The pharmaceutical excipients also include, but are not limited to: lecithin, aluminum stearate, aluminum oxide, ion exchange materials, self-emulsifying drug delivery systems, Tween or other surfactants, serum proteins, buffer substances such as phosphates, aminoacetic acid, sorbic acid, water, salts, electrolytes such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, magnesium silicate, partial glyceride mixtures of saturated fatty acids, etc.

[0034] The pharmaceutical excipients also include binders (such as microcrystalline cellulose), fillers (such as starch, glucose, anhydrous lactose and lactose beads), disintegrants (such as cross-linked PVP, cross-linked sodium carboxymethyl starch, cross-linked sodium carboxymethyl cellulose, low-substituted hydroxypropyl cellulose), lubricants (such as magnesium stearate) and absorption promoters, adsorption carriers, excipients, diluents, wetting agents, etc.

[0035] The Chinese medicine composition is made into tablets, and the preparation process is as follows: the Chinese medicine composition is passed through a 100-mesh sieve, starch and magnesium stearate are added and mixed evenly, granulated, dried, and tableted to obtain tablets; or the Chinese medicine composition is passed through a 100-mesh sieve, starch, lactose, and magnesium stearate are added and mixed evenly, granulated, dried, and tableted to obtain tablets.

[0036] The Chinese medicine composition is made into capsules, and the preparation process is as follows: the Chinese medicine composition is passed through a 100-mesh sieve, an appropriate amount of magnesium stearate is added, and the mixture is mixed and packed into hard capsules.

[0037] The Chinese medicine composition is made into pills, and the preparation process is as follows: PGE4000 is used as a matrix, the mass ratio of PGE4000 to the Chinese medicine composition is 1:1.5, and dimethyl silicone oil is used as a condensing agent to make the pills.

[0038] The Chinese medicine composition is made into an oral liquid, and the preparation process is as follows: take the Chinese medicine composition, add an appropriate amount of water to prepare an oral liquid; or take the Chinese medicine composition, add an appropriate amount of water, and then add an appropriate amount of sucrose, lactose, sorbitol and / or benzoic acid to prepare an oral liquid; or take the Chinese medicine composition, add an appropriate amount of water, and then add an appropriate amount of sucrose, citric acid, saccharin sodium, sucralose and / or sorbic acid to prepare an oral liquid; or take 5g of the Chinese medicine composition, add an appropriate amount of water, and then add an appropriate amount of sodium cyclamate. , stevioside, sodium saccharin, sucralose and / or potassium sorbate to prepare an oral liquid; or take the traditional Chinese medicine composition, add an appropriate amount of water, and then add an appropriate amount of cyclamate, stevioside, citric acid, sodium saccharin, neotame, acesulfame potassium and / or ethyl parahydroxybenzoate to prepare an oral liquid; or take the traditional Chinese medicine composition, add an appropriate amount of water, and then add an appropriate amount of cyclamate, sugar, citric acid, sodium saccharin, neotame, stevioside, acesulfame potassium and / or butyl parahydroxybenzoate to prepare an oral liquid.

[0039] The Chinese medicine composition is made into an oral liquid, and the preparation process is as follows: take the Chinese medicine composition, add an appropriate amount of water, ultrafilter, and prepare an injection; or take the Chinese medicine composition, add an appropriate amount of water, then add pharmaceutical excipients that can be used for injection, ultrafilter, and prepare an injection.

[0040] The Chinese medicine composition is prepared by the following method, comprising:

[0041] Step (1), grind the medicinal materials separately and then mix them or directly mix the medicinal materials;

[0042] Step (2), soaking in water or alcohol, boiling for 2 to 4 times, filtering, combining the filtrate, concentrating, adding ethanol until the alcohol content is 60% to 70%, and standing;

[0043] Step (3), taking the supernatant, recovering ethanol from the supernatant until there is no alcohol taste, concentrating, adding ethanol until the alcohol content is 75% to 85%, and letting it stand;

[0044] Step (4), taking the supernatant, recovering ethanol until there is no alcohol taste, adding an appropriate amount of water, refrigerating, filtering, and preparing into a liquid preparation according to a conventional process for liquid preparations, such as preparing into an oral liquid or an injection, and the injection can also be further prepared into a lyophilized powder injection; or, the filtered liquid is further concentrated, dried, and crushed, and prepared into a solid preparation, such as a tablet, a pill, a granule, a capsule, etc. according to a conventional process for solid preparations.

[0045] In step (1), the decoction is performed 2 or 3 times.

[0046] In step (2), after the filtrate is concentrated, ethanol is added until the alcohol content is about 66%.

[0047] Furthermore, the Chinese medicine composition is prepared by the following method, including: taking five medicinal materials, namely, honeysuckle, Chinese honeysuckle, Achyranthes bidentata, Scrophularia ningpoensis and Dendrobium officinale, or four medicinal materials, namely, honeysuckle, Achyranthes bidentata, Scrophularia ningpoensis and Dendrobium officinale; adding 4 to 8 times the total weight of the medicinal materials in water, soaking for 1 to 3 hours, decocting and extracting for 2 to 3 times, each time for 1 to 3 hours, combining the decoctions, filtering, concentrating the filtrate to a relative density of 1.10 to 1.30 (80°C), adding ethanol to make the alcohol content reach 60% to 80%, letting it stand, taking the supernatant, recovering the ethanol and concentrating it to a relative density of 1.25 to 1.45 (80°C), adding ethanol to make the alcohol content reach 70% to 90%, letting it stand, taking the supernatant, recovering and removing all the ethanol, adding an appropriate amount of water and refrigerating, filtering, and preparing an oral solution according to conventional processes.

[0048] As a further preferred technical solution, it also includes: adding water to 90% to 95% of the total volume of the oral liquid, refrigerating, filtering, adding stevioside and Tween-80 to make the mass fraction of stevioside in the oral liquid be 0.1 to 0.15%, and the mass fraction of Tween-80 be 4 to 6%, adjusting the pH to 8.0 to 8.6, filtering, adding the remaining water, filling, sterilizing, and obtaining the oral liquid.

[0049] When the traditional Chinese medicine composition is made into an oral liquid, the content of neochlorogenic acid is 1.90-2.00 mg / mL, the content of chlorogenic acid is 1.60-1.70 mg / mL, the content of cryptochlorogenic acid is 1.40-1.50 mg / mL, the content of β-ecdysterone is 0.20-0.30 mg / mL, the content of olibanum is 0.01-0.10 mg / mL, the content of isochlorogenic acid B is 1.40-1.50 mg / mL, the content of isochlorogenic acid A is 0.60-0.70 mg / mL, the content of cinnamic acid is 0.30-0.40 mg / mL, and the content of harpagoside is 0.01-0.10 mg / mL.

[0050] Furthermore, the content of neochlorogenic acid is about 1.982 mg / mL, the content of chlorogenic acid is about 1.647 mg / mL, the content of cryptochlorogenic acid is about 1.423 mg / mL, the content of β-ecdysterone is about 0.223 mg / mL, the content of luteolin is about 0.087 mg / mL, the content of isochlorogenic acid B is about 1.431 mg / mL, the content of isochlorogenic acid A is about 0.652 mg / mL, the content of cinnamic acid is about 0.338 mg / mL, and the content of harpagoside is about 0.074 mg / mL.

[0051] The obesity is manifested as at least one of increased body weight, lipid accumulation, disordered glucose and lipid metabolism, decreased energy metabolism level, and increased serum total cholesterol.

[0052] Furthermore, the obesity is obesity induced by a high-fat diet; the obesity induced by a high-fat diet is manifested by: weight gain, lipid accumulation, disordered glucose and lipid metabolism, decreased energy metabolism level, and increased serum total cholesterol.

[0053] Traditional Chinese medicine believes that the pathogenesis of obesity is related to qi deficiency, phlegm and dampness, and seven emotions. Its onset is often caused by damp-heat poison, which turns into heat due to blood stasis. The treatment is mainly based on removing dampness and removing blood stasis, clearing away heat and detoxifying, and tonifying the spleen and stomach. In the Chinese medicine composition of the present invention, Achyranthes bidentata removes blood stasis and dredges collaterals, cools blood and reduces swelling as the main medicine; Scrophularia ningpoensis clears heat and cools blood, and clears fire and detoxifies as the minister medicine. Flos Lonicerae is used to clear heat and detoxify, cool blood and reduce swelling, and Dendrobium nourishes yin and produces body fluid. The combination of four or five medicines can not only promote blood circulation and disperse blood stasis, but also cool blood and detoxify, so it is speculated that it can effectively treat obesity.

[0054] The use of the present invention is to administer an effective amount of the above-mentioned Chinese medicine composition to a subject or patient in need thereof. "Subject" or "patient" refers to an animal, such as a mammal, for example, a human being.

[0055] "Administering" refers to the act of giving a preparation of the present invention comprising a Chinese medicine composition to a subject. Exemplary routes of administration to the human body may be oral or injection. Administration may be one or more administrations, applications or takings, and is not intended to be limited to a specific period of time. "Administration" and "administering" are used to illustrate the act of "administering" and are used synonymously.

[0056] "Effective amount" or "therapeutically effective amount" refers to an amount of the Dendrobium preparation described herein sufficient to achieve the intended application, including but not limited to, the prevention and / or treatment of obesity. The therapeutically effective amount may vary depending on the intended application (in vitro or in vivo), or the subject and the disease condition being treated, such as the weight and age of the subject, the severity of the disease condition, the mode of administration, etc., which can be easily determined by a person of ordinary skill in the art. The specific dosage will vary depending on the dosing regimen, whether it is administered in combination with other drugs, the administration schedule, the tissue to be administered, and the physical delivery system for transport. In the present invention, "effective amount" specifically refers to an amount in which the clinical indicators and / or symptoms of obesity are improved when administered to an individual.

[0057] "Prevention" and "treatment" refer to: (1) preventing or delaying the onset of clinical symptoms of a state, disorder or condition that develops in a mammal suffering from or susceptible to the state, disorder or condition but not yet experiencing or displaying clinical or subclinical symptoms of the state, disorder or condition; (2) inhibiting the state, disorder or condition, i.e., arresting or reducing the development of the disease or at least one clinical or subclinical symptom thereof, or (3) ameliorating the disease, i.e., causing regression of the state, disorder or condition or at least one clinical or subclinical symptom thereof.

[0058] Beneficial effects of the present invention:

[0059] The Chinese medicine composition of the present invention can reduce the body weight of obese mice induced by high fat diet (HFD), improve mouse glucose metabolism disorders such as glucose tolerance and insulin tolerance, reduce the elevated TC content in mouse serum, reduce the weight of peripheral adipose tissue of mice, improve the energy metabolism level of mice, and promote the expression of genes related to fat decomposition and white fat browning, and has a good effect of treating or preventing obesity. In summary, the Chinese medicine composition has a good improvement effect on obese mice induced by high fat diet.

[0060] The Chinese medicine composition of the present invention has a simple preparation method and can be further prepared into preparations such as oral liquid. BRIEF DESCRIPTION OF THE DRAWINGS

[0061] Figure 1 is the body weight of mice during the administration period; compared with the blank group, * p<0.05, ** p<0.01, *** p<0.001; HFD+Orlistat group compared with HFD model group, & p<0.05; HFD+low-dose Chinese medicine combination group compared with HFD model group, $ p<0.05; HFD+TCM high-dose group compared with HFD model group, ## p<0.01; values=mean±SD, n=6.

[0062] Figure 2 These are H&E stained morphologies of mouse epididymal white adipose tissue (eWAT), inguinal white adipose tissue (iWAT), and brown adipose tissue (BAT).

[0063] Figure 3 The morphology of liver was stained with H&E and Oil Red O.

[0064] Figure 4 Glucose tolerance curve.

[0065] Figure 5 This is the insulin tolerance curve.

[0066] Figure 6 is the oxygen consumption of mice.

[0067] Figure 7 is the carbon dioxide exhaled by the mouse.

[0068] Figure 8 Heat generated for mice.

[0069] Fig. 9 The expression of Ucp1, Dio2, Prdm16 and Cidea genes in adipose tissue of mice.* p<0.05; compared with the HFD model group, # p<0.05; values=mean±SD, n=4.

[0070] Fig.10 is the expression of Pparγ, Atgl, Hsl, and Pgc1α genes in mouse adipose tissue. Compared with the blank group, * p<0.05; compared with the HFD model group, # p<0.05; values=mean±SD, n=4. DETAILED DESCRIPTION

[0071] The technical solution of the present invention is clearly and completely described below in conjunction with the embodiments. Through the following description, the characteristics, purposes and advantages of the present invention will be more obvious. Obviously, the described embodiments are part of the embodiments of the present invention, rather than all of the embodiments, and these embodiments cannot be understood as limiting the scope of protection claimed by the present invention. Based on the embodiments in the present invention, all other embodiments obtained by those skilled in the art without making creative work are within the scope of protection of the present invention. For those skilled in the art, without departing from the premise of the present invention, several deformations and improvements can also be made, which should also be regarded as the scope of protection of the present invention, and these will not affect the effect of the implementation of the present invention and the practicality of the patent.

[0072] Unless otherwise defined, all professional and scientific terms used herein have the same meanings as those familiar to those skilled in the art. In addition, any methods and materials similar or equivalent to those described herein can be applied to the methods of the present invention. The preferred implementation methods and materials described herein are for demonstration purposes only.

[0073] The experimental methods in the following examples without specifying specific conditions can be implemented according to conventional conditions or conditions recommended by the manufacturer.

[0074] The medicinal materials Achyranthes bidentata, Scrophularia ningpoensis, Dendrobium officinale, Honeysuckle and Flos Lonicerae were all purchased from the medicinal material market and were identified as authentic.

[0075] Example 1

[0076] The Chinese medicine composition is prepared from honeysuckle, honeysuckle flower, Achyranthes bidentata, Scrophularia ningpoensis and Dendrobium officinale as raw materials, and the mass ratio of honeysuckle, honeysuckle flower, Achyranthes bidentata, Scrophularia ningpoensis and Dendrobium officinale is 16:9:25:25:25.

[0077] The Chinese medicine composition is made into an oral liquid, and the specific preparation method is as follows:

[0078] 272g of honeysuckle, 153g of Chinese honeysuckle, 425g of Achyranthes bidentata, 425g of Scrophularia ningpoensis and 425g of Dendrobium officinale; soak the 5 medicinal materials in 6 times the total weight of water for 2 hours, decoct twice, each time for 1.5 hours, combine the decoctions, filter, concentrate the filtrate to a relative density of 1.16 (80°C), add ethanol to an alcohol content of 66%, let stand, take the supernatant, recover the ethanol and concentrate to a relative density of 1.36 (80°C), add ethanol to an alcohol content of 80%, let stand, take the supernatant, recover all the ethanol, add water to 950mL, refrigerate, filter, add 1.2g of stevioside and 5g of Tween-80, adjust the pH to 8.0, filter, add water to 1000mL, seal, and sterilize to obtain an oral solution.

[0079] Example 2

[0080] Take 1275g of honeysuckle, 1275g of Achyranthes bidentata, 425g of Scrophularia ningpoensis, and 425g of Dendrobium officinale (the mass ratio of the four is 3:3:1:1), soak in water, decoct twice, filter, and combine the filtrate. Concentrate the filtrate, add ethanol to an alcohol content of 66%, let stand, take the supernatant, recover ethanol, concentrate, add ethanol to an alcohol content of 80%, let stand, take the supernatant, recover ethanol, concentrate, vacuum dry, and crush into fine powder.

[0081] Example 3

[0082] Take 850g of honeysuckle, 850g of Achyranthes bidentata, 425g of Scrophularia ningpoensis, and 425g of Dendrobium officinale (the mass ratio of the four is 2:2:1:1), soak in water, decoct twice, filter, and combine the filtrate. Concentrate the filtrate, add ethanol to an alcohol content of 66%, let stand, take the supernatant, recover ethanol, concentrate, add ethanol to an alcohol content of 80%, let stand, take the supernatant, recover ethanol, concentrate, vacuum dry, and crush into fine powder.

[0083] Example 4

[0084] Take 1275g of honeysuckle, 850g of Achyranthes bidentata, 425g of Scrophularia ningpoensis, and 425g of Dendrobium officinale (the mass ratio of the four is 3:2:1:1), soak in water, decoct twice, filter, and combine the filtrate. Concentrate the filtrate, add ethanol to an alcohol content of 66%, let stand, take the supernatant, recover ethanol, concentrate, add ethanol to an alcohol content of 80%, let stand, take the supernatant, recover ethanol, concentrate, vacuum dry, and crush into fine powder.

[0085] Example 5

[0086] Take 850g of honeysuckle, 1275g of Achyranthes bidentata, 425g of Scrophularia ningpoensis, and 425g of Dendrobium officinale (the mass ratio of the four is 2:3:1:1), soak in water, decoct twice, filter, and combine the filtrate. Concentrate the filtrate, add ethanol to 66% alcohol content, let stand, take the supernatant, recover ethanol, concentrate, add ethanol to 80% alcohol content, let stand, take the supernatant, recover ethanol, concentrate, vacuum dry, and crush into fine powder.

[0087] Example 6

[0088] Take 425g of honeysuckle, 1275g of Achyranthes bidentata, 425g of Scrophularia ningpoensis, and 425g of Dendrobium officinale (the mass ratio of the four is 1:3:1:1), soak in water, decoct twice, filter, and combine the filtrate. Concentrate the filtrate, add ethanol to 66% alcohol content, let stand, take the supernatant, recover ethanol, concentrate, add ethanol to 80% alcohol content, let stand, take the supernatant, recover ethanol, concentrate, vacuum dry, and crush into fine powder.

[0089] Example 7

[0090] Take 425g of honeysuckle, 850g of Achyranthes bidentata, 425g of Scrophularia ningpoensis, and 425g of Dendrobium officinale (the mass ratio of the four is 1:2:1:1), soak in water, decoct twice, filter, and combine the filtrate. Concentrate the filtrate, add ethanol to an alcohol content of 66%, let stand, take the supernatant, recover ethanol, concentrate, add ethanol to an alcohol content of 80%, let stand, take the supernatant, recover ethanol, concentrate, vacuum dry, and crush into fine powder.

[0091] Example 8

[0092] Take 850g of honeysuckle, 425g of Achyranthes bidentata, 425g of Scrophularia ningpoensis, and 425g of Dendrobium officinale (the mass ratio of the four is 2:1:1:1), soak in water, decoct twice, filter, and combine the filtrate. Concentrate the filtrate, add ethanol to an alcohol content of 66%, let stand, take the supernatant, recover ethanol, concentrate, add ethanol to an alcohol content of 80%, let stand, take the supernatant, recover ethanol, concentrate, vacuum dry, and crush into fine powder.

[0093] Example 9

[0094] Take 1275g of honeysuckle, 425g of Achyranthes bidentata, 425g of Scrophularia ningpoensis, and 425g of Dendrobium officinale (the mass ratio of the four is 3:1:1:1), soak in water, decoct twice, filter, and combine the filtrate. Concentrate the filtrate, add ethanol to an alcohol content of 66%, let stand, take the supernatant, recover ethanol, concentrate, add ethanol to an alcohol content of 80%, let stand, take the supernatant, recover ethanol, concentrate, vacuum dry, and crush into fine powder.

[0095] Example 10

[0096] Take 425g of honeysuckle, 425g of Achyranthes bidentata, 425g of Scrophularia ningpoensis, and 425g of Dendrobium officinale (the mass ratio of the four is 1:1:1:1), soak in water, decoct twice, filter, and combine the filtrate. Concentrate the filtrate, add ethanol to 60% alcohol content, let stand, take the supernatant, recover ethanol, concentrate, add ethanol to 75% alcohol content, let stand, take the supernatant, recover ethanol, concentrate, vacuum dry, and crush into fine powder.

[0097] Embodiment 11

[0098] Take 425g of honeysuckle, 425g of Achyranthes bidentata, 425g of Scrophularia ningpoensis, and 425g of Dendrobium officinale (the mass ratio of the four is 1:1:1:1), soak in water, decoct twice, filter, and combine the filtrate. Concentrate the filtrate, add ethanol to an alcohol content of 70%, let stand, take the supernatant, recover ethanol, concentrate, add ethanol to an alcohol content of 85%, let stand, take the supernatant, recover ethanol, concentrate, vacuum dry, and crush into fine powder.

[0099] Example 12

[0100] Take 425g of honeysuckle, 425g of Achyranthes bidentata, 425g of Scrophularia ningpoensis, and 425g of Dendrobium officinale (the mass ratio of the four is 1:1:1:1), soak in water, decoct twice, filter, and combine the filtrate. Concentrate the filtrate, add ethanol to 60% alcohol content, let stand, take the supernatant, recover ethanol, concentrate, add ethanol to 85% alcohol content, let stand, take the supernatant, recover ethanol, concentrate, vacuum dry, and crush into fine powder.

[0101] Example 13

[0102] Take 425g of honeysuckle, 425g of Achyranthes bidentata, 425g of Scrophularia ningpoensis, and 425g of Dendrobium officinale (the mass ratio of the four is 1:1:1:1), soak in water, decoct twice, filter, and combine the filtrate. Concentrate the filtrate, add ethanol to 70% alcohol content, let stand, take the supernatant, recover ethanol, concentrate, add ethanol to 75% alcohol content, let stand, take the supernatant, recover ethanol, concentrate, vacuum dry, and crush into fine powder.

[0103] Embodiment 14

[0104] Determination of the content of main components in traditional Chinese medicine compositions

[0105] (1) Experimental Materials and Methods

[0106] Preparation of test solution: oral solution was prepared according to Example 1, and three batches of the prepared oral solution were taken and named SHZJ-1, SHZJ-2 and SHZJ-3 respectively, and filtered through a 0.22 μm filter membrane respectively, and the filtrate was taken and sampled for analysis.

[0107] Preparation of reference solution: Weigh appropriate amount of neochlorogenic acid, chlorogenic acid, cryptochlorogenic acid, β-ecdysterone, luteolin, isochlorogenic acid B, isochlorogenic acid A, cinnamic acid, and harpaoside reference substances respectively, weigh accurately, place in a 5 mL volumetric flask, add appropriate amount of 70% methanol, heat and ultrasonically dissolve, cool and dilute to the scale, shake well to obtain a mixed reference solution with solubility of 729.8, 746.0, 652.8, 1166.2, 1402.1, 687.2, 789.7, 3010.1, and 948.1 μg / mL for neochlorogenic acid, chlorogenic acid, cryptochlorogenic acid, β-ecdysterone, luteolin, isochlorogenic acid B, isochlorogenic acid A, cinnamic acid, and harpaoside, respectively.

[0108] (2) Content determination

[0109] Chromatographic conditions:

[0110] Agilent 1200 HPLC; CAPCELL PAK AQ C 18 Chromatographic column (250nm×4.6mm, 5μm); mobile phase A: methanol, B: 0.2% formic acid solution; gradient elution according to Table 1; flow rate 1.0mL / min, column temperature 30℃, detection wavelength 254nm, injection volume 2μL (test solution) and 10μL (reference solution).

[0111] Table 1. Gradient elution program

[0112]

[0113]

[0114] (3) Experimental results

[0115] The contents of the main chemical components in the Chinese medicine composition are shown in Table 2.

[0116] Table 2. Content of main components in traditional Chinese medicine composition (mg / mL)

[0117]

[0118] Embodiment 15

[0119] The therapeutic effect of the Chinese medicine composition on obesity was evaluated using a high-fat diet (HFD)-induced obesity animal model. The specific method is as follows:

[0120] (1) Experimental Materials

[0121] Experimental animals: SPF-grade C57BL / 6 male mice, weighing 12-16 g (4 weeks old), were purchased from Shanghai Slake Experimental Animal Co., Ltd. and raised in the Experimental Animal Center of Shanghai University of Traditional Chinese Medicine. The mice were raised at a temperature of (22±1)°C, a relative humidity of (65±10)%, and a 12h / 12h light cycle.

[0122] Test drugs: Using Achyranthes bidentata, Scrophularia ningpoensis, Dendrobium officinale, Flos Lonicerae, and Flos Lonicerae (purchased from the medicinal material market and identified as genuine products) as raw materials, oral liquid was prepared according to the preparation method of Example 1. The positive drug was Orlistat (commercially available).

[0123] (2) Experimental methods

[0124] Animal experiment scheme: C57BL / 6 male mice were randomly divided into 5 groups, 6 mice in each group. Grouping: NCD group (blank control group); HFD group (model group); HFD+Orlistat group (positive drug group, the dosage is 20 mg / kg, using 0.5% sodium carboxymethyl cellulose solution to prepare a suspension, oral administration); HFD+low-dose group of traditional Chinese medicine composition (the dosage is equivalent to 13.26 g / kg of the original oral solution, oral administration); HFD+high-dose group of traditional Chinese medicine composition (the dosage is equivalent to 66.30 g / kg of the original oral solution, oral administration).

[0125] After 1 week of adaptive feeding, the mice in the NCD group were fed with ordinary feed every day, and the rest of the mice were fed with high-fat feed. After 8 weeks of feeding, the mice fed with high-fat feed were randomly and evenly divided into HFD group, HFD+Orlistat group, HFD+low-dose Chinese medicine composition group, and HFD+high-dose Chinese medicine composition group. The four groups of mice were given drug intervention every day for 4 weeks. The body weight and food intake of the mice were monitored during the administration period, and the glucose tolerance and insulin resistance of the mice were tested at the end of the administration. After the animals were killed, the liver tissue was taken, quickly frozen in liquid nitrogen, and stored at -80°C for later use.

[0126] Glucose tolerance test: After 4 weeks of administration, mice in each group fasted for 16 hours, and their fasting blood glucose was measured by tail tip blood sampling. Then, glucose (2 g / kg) was injected intraperitoneally, and the result was recorded as 0 min. Blood glucose levels were measured by tail tip blood sampling at 15, 30, 60, and 120 minutes after injection.

[0127] Insulin tolerance test: After 4 weeks of administration, mice in each group fasted for 4 hours, and their fasting blood glucose was measured by tail tip blood sampling. Then, insulin (0.75 U / kg) was injected intraperitoneally, and the result was recorded as 0 min. Blood glucose levels were measured by tail tip blood sampling at 15, 30, 60, and 120 minutes after injection.

[0128] H&E staining of liver tissue and adipose tissue for morphological observation: Liver tissue, epididymal white adipose tissue (eWAT), inguinal white adipose tissue (iWAT) and brown adipose tissue (BAT) from the same part (liver lobule) of mice were taken for pathological examination. The samples were fixed with 10% formaldehyde solution, embedded in paraffin and sliced. Some of the paraffin sections were kept for later use, and some were stained with hematoxylin-eosin and observed under an optical microscope to evaluate the morphological changes in each group.

[0129] Oil red staining of liver tissue for morphological observation: liver tissues from the same site (liver lobule) were taken for pathological examination, fixed with 4% paraformaldehyde solution, embedded in paraffin, sliced, and stained with Oil red O dye to evaluate the lipid accumulation in rat liver.

[0130] Detection of total cholesterol (TC) content in serum: Take serum samples from each group of mice as test samples. Select a blank well, a standard well, and the others as sample wells in a 96-well plate. Add 2.5 μL of distilled water, standard, and sample to the blank well, standard well, and sample well, respectively. Add 250 μL of working solution to each well, mix well, incubate at 37°C for 10 minutes, and use a microplate reader to measure the absorbance of each well at a wavelength of 510 nm. The concentration of the standard is 5.17 mmol / L, and the specific calculation formula is as follows:

[0131] TC content in serum sample (mmol / L) = (sample OD value - blank OD value) ÷ (standard OD value - blank OD value) × standard concentration (mmol / L)

[0132] Energy metabolism measurement of mice: 4 weeks after administration, the mice were placed in energy metabolism cages (single cage housing), and each mouse was given sufficient feed and drinking water. After the mice adapted to the metabolic cages for 24 hours, the metabolic cage detection instrument was turned on, and after the machine stabilized, metabolic indicators such as oxygen consumption, carbon dioxide exhalation, and heat generation of each mouse within 24 hours were detected.

[0133] Total RNA extraction: 100 mg of adipose tissue was cut and placed in a 1.5 mL centrifuge tube. After adding 1 mL of Trizol to homogenize, the tube was allowed to stand on ice for 5 min. 200 μL of chloroform was added and shaken for 15 s. The tube was centrifuged at 4°C and 12,000 × g for 15 min. The colorless water layer was transferred to a new tube and 250 μL of isopropanol was added and shaken thoroughly and allowed to stand for 10 min. The tube was centrifuged at 4°C and 12,000 × g for 10 min to obtain RNA precipitation. The supernatant was discarded. 1 mL of pre-cooled 75% ethanol was added. The tube was centrifuged at 4°C and 7,500 × g for 5 min. After centrifugation, the ethanol was discarded. After the precipitate was dried, 200 μL of DEPC water was added to fully dissolve it. The resulting solution was the RNA solution. The concentration of RNA in each sample was measured and stored at -80°C for later use.

[0134] Reverse transcription: Prepare the reverse transcription system, add the corresponding reagents according to the instructions of the kit, and mix thoroughly. React at 37℃ for 30min, and 85℃ for 1min. Perform reverse transcription according to this program temperature. After reverse transcription, store the cDNA sample at -80℃ for later use.

[0135] Real-time PCR: Prepare the reaction system according to the kit instructions, with a sample volume of 10 μL. Perform the Real-time PCR amplification experiment according to the instrument instructions.-ΔΔ The Ct method was used to calculate the difference in gene expression between the two groups.

[0136] Table 3. Primer sequences

[0137]

[0138] (3) Data Statistics

[0139] The experimental data were expressed as mean ± standard deviation (Mean ± SD), and SPSS 16.0 software was used for statistical analysis. One-Way ANOVA statistical method was used for variance analysis between groups. All data were expressed as mean ± standard deviation (Mean ± SD).

[0140] (4) Experimental results

[0141] Effects of Chinese herbal medicine combination on body weight, peripheral adipose tissue weight and morphology of HFD-induced obese mice

[0142] The final body weight (Final body weight) and relative weight of white adipose tissue (eWATweight / body weight: weight of epididymal white adipose tissue relative to body weight; iWAT weight / body weight: weight of inguinal white adipose tissue relative to body weight) of mice in different groups were statistically analyzed. The results showed that compared with the mice in the NCD group, the body weight and relative weight of white adipose tissue of the mice in the HFD group were significantly increased, and the lipid droplets in the adipocytes were enlarged, indicating that the obese mouse model was successfully established. The administration of the Chinese medicine composition to high and low dose groups can reduce the body weight of obese mice to varying degrees, and the efficacy is not significantly different from that of the positive drug ( Figure 1 After administration of the Chinese medicine composition, the relative weight of the white adipose tissue of obese mice was also significantly reduced, and the efficacy was not significantly different from that of the positive drug (Table 4). The results of H&E staining of adipose tissue showed that the lipid droplets in the adipocytes of mice in the HFD group increased, and the lipid droplets in the adipose tissue were significantly reduced after administration of the Chinese medicine composition ( Figure 2 ). The above results suggest that administration of the Chinese medicine composition can significantly reduce the body weight, peripheral adipose tissue weight and its morphology of obese mice, and reduce the formation of lipid droplets in adipose tissue.

[0143] Table 4. Chinese herbal medicine composition reduces the final body weight, iWAT, and eWAT relative weight of HFD-induced obese mice

[0144]

[0145] Note: Compared with the blank control group, ** p<0.01, *** p<0.001; HFD+Orlistat group compared with HFD model group, &p<0.05; HFD+low-dose Chinese medicine combination group compared with HFD model group, $ p<0.05, $$ p<0.01; HFD+TCM high-dose group compared with HFD model group, ## p<0.01; values=mean±SD, n=6.

[0146] Chinese herbal medicine composition reduces elevated TC content in serum of HFD-induced obese mice

[0147] The experimental results are shown in Table 5, which show that the TC content in the serum of the HFD group mice was significantly increased compared with the NCD group mice; different doses of the Chinese medicine composition can reduce the TC content in the serum of the mice, and the efficacy is not significantly different from that of the positive drug. This indicates that the Chinese medicine composition can reduce the elevated TC content in the serum of obese mice.

[0148] Table 5. The Chinese herbal medicine composition reduces the elevated TC content in serum of HFD-induced obese mice

[0149]

[0150] Note: Compared with the blank control group, *** p<0.001; compared with the HFD model group, ### p<0.001; values=mean±SD, n=6.

[0151] Chinese herbal medicine combination improves liver lipid accumulation in HFD-induced obese mice

[0152] The results of liver tissue Oil Red O and H&E sections are shown in Figure 3 , showing that the administration of the Chinese medicine composition can significantly reduce the accumulation of lipids in the liver, lipid vacuoles and ballooning of hepatocytes. The above results suggest that the Chinese medicine composition can significantly improve the lipid accumulation and degeneration of the liver in the process of HFD-induced obese mice.

[0153] SHZJ improves glucose tolerance and insulin resistance in HFD-induced obese mice

[0154] Figure 4 , Figure 5Table 6 shows the area under the curve of glucose tolerance (AUC of GTT) and the area under the curve of insulin resistance (AUC of ITT) of each group of mice. The experimental results show that after intraperitoneal injection of glucose in each group of mice, compared with the NCD group mice, the blood sugar of the HFD group mice increased rapidly and then slowly decreased. After the administration of the Chinese medicine composition, the increased blood sugar decreased rapidly, and the return time was significantly reduced ( Figure 4 ). After intraperitoneal injection of insulin in each group of mice, the blood sugar level of the HFD group mice decreased slowly compared with the NCD group, indicating that their sensitivity to insulin was reduced. After administration of the Chinese medicine composition, the blood sugar level of the obese mice decreased rapidly ( Figure 5 ), wherein the efficacy of the Chinese medicine composition was not significantly different from that of the positive drug. The above results suggest that the Chinese medicine composition can improve glucose tolerance and insulin resistance in HFD-induced obese mice.

[0155] Table 6. Chinese herbal medicine composition improves glucose tolerance and insulin resistance in HFD-induced obese mice

[0156]

[0157] Note: Compared with the blank group, *** p<0.001; compared with the HFD model group, # p<0.05, ### p<0.001; values=mean±SD, n=6.

[0158] Chinese herbal medicine combination improves energy metabolism in HFD-induced obese mice

[0159] The experimental results showed that compared with the NCD group mice, the oxygen consumption, carbon dioxide exhalation and heat generation of the HFD group mice were significantly reduced, indicating that the energy metabolism level of obese mice was significantly reduced. After drug intervention with the Chinese medicine composition, the oxygen consumption of obese mice ( Figure 6 ), exhaled carbon dioxide ( Figure 7 ) and the heat generated and the total energy metabolism during the day and night ( Figure 8 , Table 7) were significantly increased, and there was no significant difference in efficacy between the positive drugs and the positive drugs, indicating that the Chinese medicine composition can significantly improve the energy metabolism level of obese mice.

[0160] Table 7. Drug combination improves total circadian energy metabolism in HFD-induced obese mice

[0161]

[0162] Note: Compared with the blank group,*** p<0.001; compared with the HFD model group, ### p<0.001; values=mean±SD, n=4.

[0163] Chinese herbal medicine combination improves thermogenesis and lipid decomposition-related gene expression in inguinal white adipose tissue of HFD-induced obese mice

[0164] Adipose tissue is divided into white adipose tissue and brown adipose tissue. White adipose tissue is composed of a large number of lipid droplets and is used for energy storage in the body, while brown fat contains abundant mitochondria and can consume energy through non-shivering thermogenesis dependent on mitochondrial uncoupling protein 1 (UCP1). It is currently believed that promoting the transformation of white adipose tissue to brown fat to increase energy consumption is an important intervention measure to improve obesity. High levels of UCP1 can weaken the proton electrochemical gradient on the mitochondrial membrane, thereby uncoupling the energy of oxidative phosphorylation to generate heat and promote energy consumption. UCP1 and lipid droplet-associated protein-cell death-inducing DFFA-like effector A (Cidea) are considered to be markers of brown fat. In addition, adipocytes can promote the conversion of thyroxine to triiodothyronine through iodothyronine deiodinase II (DIO2), thereby regulating UCP1 expression and promoting increased thermogenesis in adipose tissue. At the same time, PR domain-containing 16 (PRDM16), peroxisome proliferator-activated receptor gamma (PPARγ) and peroxisome proliferator-activated receptor-gamma coactivator 1-α (PGC-1α) are considered to be important proteins involved in promoting adipocyte differentiation. The main hydrolases used to hydrolyze triglycerides in adipose tissue are triglyceride lipase (ATGL) and hormone-sensitive lipase (HSL), and the fatty acids generated by hydrolysis partially act on adipocytes for metabolic consumption.

[0165] Real-time-PCR experimental results are shown in Fig. 9 , Fig.10The results showed that the Chinese medicine composition can significantly increase the expression of genes such as Pparγ, Atgl, Hsl, Pgc1α, Ucp1, Dio2, Prdm16, and Cidea. Among them, the increased expression of Atgl and Hsl genes can promote the hydrolysis of triglycerides in adipose tissue, and the increased expression of Pparγ, Pgc1α, Ucp1, Dio2, Prdm16 and Cidea genes can promote the browning of white fat, thereby causing adipose tissue to consume fatty acids in the form of heat energy.

[0166] In summary, the Chinese medicine composition can promote fat decomposition and browning of white fat, enhance its heat production capacity, increase energy consumption, and thus play a role in improving obesity.

[0167] The above features mentioned in the present invention or the features mentioned in the embodiments can be combined in any way. All the features disclosed in the present specification can be used in any combination form, and each feature disclosed in the specification can be replaced by any alternative feature that can provide the same, equal or similar purpose. Therefore, unless otherwise specified, the disclosed features are only general examples of equal or similar features.

Claims

1. Use of a Chinese medicine composition in the preparation of medicines and / or health products for treating and / or preventing obesity, wherein the Chinese medicine composition is made of honeysuckle, Chinese honeysuckle, Achyranthes bidentata, Scrophularia ningpoensis and Dendrobium officinale as raw materials, the mass ratio of the total amount of honeysuckle and Chinese honeysuckle to Achyranthes bidentata, Scrophularia ningpoensis and Dendrobium officinale is (1-200):(1-200):(1-200):(1-200), and the mass ratio of honeysuckle to Chinese honeysuckle is 16:9; or the Chinese medicine composition is made of honeysuckle, Achyranthes bidentata, Scrophularia ningpoensis and Dendrobium officinale as raw materials, the mass ratio of honeysuckle to Achyranthes bidentata, Scrophularia ningpoensis and Dendrobium officinale is (1-200):(1-200):(1-200):(1-200).

2. The use according to claim 1, Features: The total amount of honeysuckle and Chinese honeysuckle or the mass ratio of honeysuckle to Achyranthes bidentata, Scrophularia ningpoensis and Dendrobium officinale is (1-3):(1-3):1:

1.

3. The use according to claim 2, Features: The total amount of honeysuckle and Chinese honeysuckle or the mass ratio of honeysuckle to Achyranthes bidentata, Scrophularia ningpoensis and Dendrobium officinale is 3:1:1:1, 2:1:1:1, 3:2:1:1, 3:3:1:1, 3:3:2:1, 3:3:3:1, 3:3:3:2, 1:2:1:1, 1:3:1:1, 2:3:1:1, 2:2:1:1, 1:1:1:

1.

4. The use according to claim 1, Features: The traditional Chinese medicine composition is prepared from honeysuckle, honeysuckle, achyranthes bidentata, scrophularia ningpoensis and dendrobium in a mass ratio of 16:9:25:25:

25.

5. The use according to claim 1, Features: The traditional Chinese medicine composition comprises neochlorogenic acid, chlorogenic acid, cryptochlorogenic acid, β-ecdysterone, luteolin, isochlorogenic acid B, isochlorogenic acid A, cinnamic acid and harpagoside.

6. The use according to claim 1, Features: The Chinese medicine composition and pharmaceutical excipients are prepared into a preparation, and the preparation is a solid preparation, an oral liquid preparation or an injectable liquid preparation.

7. The use according to claim 6, Features: The Chinese medicine composition is prepared by the following method, comprising: Step (1), grind the medicinal materials separately and then mix them or directly mix the medicinal materials; Step (2), soaking in water or alcohol, boiling for 2 to 4 times, filtering, combining the filtrate, concentrating, adding ethanol until the alcohol content is 60% to 70%, and standing; Step (3), taking the supernatant, recovering ethanol from the supernatant until there is no alcohol taste, concentrating, adding ethanol until the alcohol content is 75% to 85%, and letting it stand; Step (4), taking the supernatant, recovering ethanol until there is no alcohol taste, adding an appropriate amount of water, refrigerating, filtering, and preparing a liquid preparation according to a conventional process for liquid preparations; or, concentrating the filtered liquid, drying, crushing, and preparing a solid preparation according to a conventional process for solid preparations.

8. The use according to claim 1, Features: The preparation is prepared by the following method: the Chinese medicine composition is prepared by the following method, comprising: taking five kinds of medicinal materials, namely honeysuckle, Chinese honeysuckle, Achyranthes bidentata, Scrophularia ningpoensis and Dendrobium officinale, or four kinds of medicinal materials, namely honeysuckle, Achyranthes bidentata, Scrophularia ningpoensis and Dendrobium officinale; adding water 4 to 8 times the total weight of the medicinal materials, soaking for 1 to 3 hours, decocting and extracting for 2 to 3 times, each time for 1 to 3 hours, combining the decoctions, filtering, concentrating the filtrate to a relative density of 1.10 to 1.30 at 80°C, adding ethanol to make the alcohol content reach 60% to 80%, standing, taking the supernatant, recovering the ethanol and concentrating to a relative density of 1.25 to 1.45 at 80°C, adding ethanol to make the alcohol content reach 70% to 90%, standing, taking the supernatant, recovering and removing all the ethanol, adding an appropriate amount of water for refrigeration, filtering, and preparing an oral liquid according to a conventional process.

9. The use according to claim 1, Features: The obesity is manifested as at least one of increased body weight, lipid accumulation, disordered glucose and lipid metabolism, decreased energy metabolism level, and increased serum total cholesterol.

10. The use according to claim 1, Features: The obesity is obesity induced by a high-fat diet.

Images